Drug Type Small molecule drug |
Synonyms BEBT-109, KCBT-1083 |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 01 Jul 2024 | |
EGFR ex20ins mutation in non-small cell lung cancer | Phase 2 | CN | 11 Jul 2022 | |
EGFR positive non-small cell lung cancer | Phase 2 | CN | 13 Apr 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | CN | 15 Jan 2020 |